AI Article Synopsis
- Treatment for AML and high-risk MDS patients who cannot undergo intensive chemotherapy is challenging, but a study enrolled 154 patients to test the D-IA regimen (decitabine, idarubicin, and cytarabine).
- After two treatment cycles, the overall response rates were 66.4% for AML and 76.6% for MDS, with 2-year survival rates of 29% and 31%, respectively.
- Additionally, some patients who achieved complete remission underwent allo-HSCT, leading to significantly longer survival times compared to those who did not receive the transplant.
Article Abstract
Treatment for acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy is a major challenge for clinicians. We enrolled 154 patients ineligible for intensive chemotherapy who were prescribed D-IA regimen (decitabine 15-20 mg/m days 1 to 3-5, followed by idarubicin 3 mg/m for 5-7 days and cytarabine 30 mg/m for 7-14 days). For AML and MDS patients, the overall response rate after two cycles was 66.4% and 76.6%, respectively, and the 2-year overall survival rates were 29% and 31%, respectively. Fourteen (13.1%) AML and five (10.6%) MDS patients underwent allo-HSCT after complete remission. The allo-HSCT group survival time was significantly longer than the control group (median survival time not reached in HSCT group, 13 and 18.5 months in non-HSCT AML and MDS group). We concluded that D-IA regimen was effective and well tolerated for patients with AML or higher-risk MDS ineligible for intensive chemotherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10428194.2021.1891230 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!